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Objective: Cell transplantation to prevent congestive heart failure in patients with
inherited dilated cardiomyopathy might require the use of noncardiac donor cells
unaffected by the genetic defect and cryopreservation to permit cell storage until the
time of transplantation. However, the effects of cryopreservation on peripheral
muscle cells harvested from a cardiomyopathic recipient and their subsequent ability
to restore cardiac structure and function after transplantation are unknown.
Methods: Skeletal myoblasts and vascular smooth muscle cells from cardiomyo-
pathic hamsters (-sarcoglycan–deficient BIO 53.58 hamster) and age-matched
normal donor hamsters were isolated, expanded in culture, and cryopreserved. After
reanimation in culture, cell morphology and growth rate were assessed and com-
pared with values seen in noncryopreserved cells. A total of 4  106 previously
cryopreserved skeletal myoblasts (n  10) and vascular smooth muscle cells (n 
10) harvested from cardiomyopathic donors were then transplanted into the left
ventricles of 17-week-old BIO 53.58 hamsters. Hearts injected with culture medium
alone (n  11) served as controls. Heart function was assessed 5 weeks after
transplantation on a Langendorff apparatus, and left ventricular geometry was
quantified by means of computerized planimetry. Staining with 5-bromo-2'-de-
oxyuridine identified the injected cells.
Results: Vascular smooth muscle cells from cardiomyopathic donors had an abnor-
mal morphology and diminished growth rates in culture compared with vascular
smooth muscle cells from normal donors. These markers of injury were exacerbated
by cryopreservation. In contrast, vascular smooth muscle cells from normal donors
and skeletal myoblasts from either cardiomyopathic or normal donors appeared
normal in culture and were unaffected by cryopreservation. Both cryopreserved
vascular smooth muscle cells and skeletal myoblasts from cardiomyopathic donors
formed a viable muscle-resembling tissue that prevented wall thinning, limited left
ventricular dilatation, and preserved global systolic function in hamsters with a
genetic dilated cardiomyopathy. However, attenuation of cardiac remodeling and
preservation of global heart function was greater after skeletal myoblast transplan-
tation compared with vascular smooth muscle cell transplantation in parallel to the
in vitro morphologic and growth characteristics of these cells.
Conclusions: Cryostorage of healthy donor cells does not prevent the benefits of cell
transplantation on limiting remodeling and preserving cardiac function in the failing
heart. The health of donor cells in vitro predicts their subsequent benefits on cardiac
structure and function after transplantation. Cryopreservation of donor cells might
facilitate a clinically applicable and effective approach for ventricular restoration
with cell-transplantation therapy for patients with inherited dilated cardiomyopathy.
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Cell transplantation has been demonstratedto prevent cardiac dilatation and dysfunc-tion after myocardial injury, such as thatcaused by coronary ischemia, infarction, orlocal cryoinjury.1-6 In addition, we and oth-ers found that cell transplantation pre-
served ventricular function in animals with a progressive
dilated cardiomyopathy.7-9 However, the clinical applicabil-
ity of these encouraging early results was limited by the cell
types used and the subsequent timing of transplantation.
First, given the global nature of the disease, cardiac muscle
cells might be abnormal in patients with a dilated cardio-
myopathy. Extracardiac muscle cells, such as peripheral
skeletal muscle cells (SKMCs) or vascular smooth muscle
cells (VSMCs), might eliminate the need for transplantation
of diseased cardiac cells. Second, in our previous studies the
duration from cell harvest to cell transplantation was not
flexible and was determined by the growth rate of the cells
in culture. Cryopreservation might provide a safe method
for donor cell storage, allowing for targeted cell therapy, but
no study to date has examined the effects of cryopreserva-
tion on the ability of donor cells to restore cardiac structure
and function. In addition, it is not known whether the
growth characteristics of cells in culture are predictive of
their subsequent benefits after transplantation. The ability to
identify cells in culture that are capable of providing bene-
fits after cell transplantation, particularly after a period of
prolonged storage, would facilitate and optimize clinical
cell-transplantation therapies.
The objectives of this study were 2-fold. First, we aimed
to establish a proof of concept that peripheral muscle cells
can be safely cryopreserved, reanimated in culture, and then
transplanted into cardiomyopathic hearts, resulting in im-
proved left ventricular (LV) structure and function. Second,
the in vitro characteristics of the cells were assessed to
evaluate tolerance to cryostorage and also to determine the
feasibility of using in vitro characteristics to predict subse-
quent in vivo effects after cryostorage and transplantation.
Material and Methods
Experimental Design
The design of this study is described in Figure 1. First, the
differential effects of cryostorage on SKMC and VSMC survival,
growth, and morphology in culture were assessed from cardiomyo-
pathic hamsters with an underlying genetic defect (-sarcoglycan–
deficient BIO 53.58 hamsters) versus similar cells from normal
hamster donors. Second, the cryopreserved SKMCs and VSMCs
from cardiomyopathic donors were transplanted into 17-week-old
cardiomyopathic recipient hamsters to evaluate the ability of myo-
pathic cells to improve LV structure and function after a period of
cryostorage and to simulate a clinical scenario. The in vitro char-
acteristics of the cells were then compared with their subsequent
ability to restore ventricular function to determine the feasibility of
using in vitro characteristics to predict subsequent in vivo effects
after cryostorage and transplantation.
Experimental Animals
All procedures and protocols were approved by the Animal Care
Committee of the University Health Network (Toronto, Ontario,
Canada). Male BIO 53.58 hamsters (BIO Breeders) and normal
Mongolian hamsters were used in the study. Donor muscle cells
were freshly isolated from 4-week old BIO 53.58 hamsters. Sev-
enteen-week-old BIO 53.58 hamsters were used as recipients. All
experiments were performed in accordance with the “Guide to the
Care and Use of Experimental Animals” of the Canadian Council
on Animal Care” and the “Guide of the Care and Use of Labora-
tory Animals” (National Institutes of Health publication no. 85-23,
revised 1985).
The animals were divided into 4 groups according to the
specific procedure performed: SKMC transplantation (SKMC
group, n  10), VSMC transplantation (VSMC group, n  10),
culture medium injected without donor cells (control group, n 
11), and age-matched normal hamsters without any surgical inter-
vention (normal group, n  7).
Isolation, Culture, Cryopreservation, and
Identification of Donor Cells
Cell isolation and culture. Biopsy specimens of the skeletal
muscle and aorta were collected from donor hamsters (4-week-old
BIO 53.58 hamsters). Immediately after being killed, the bilateral
thigh muscles and the whole aorta were excised and processed for
cell culture. One hamster provided approximately 4 transplantation
donor cells. The thigh muscle was minced and incubated in 20 mL
of phosphate-buffered saline (PBS; NaCl, 136.9 mmol/L; KCl, 2.7
mmol/L; Ma2HPO4, 8.1 mmol/L; KH2PO4, 1.5 mmol/L; pH 7.3)
containing 0.2% Type I collagenase (Sigma) and 0.02% glucose at
37°C for 15 minutes. After centrifugation at 600g for 5 minutes at
room temperature, the cell pellet was isolated, and the supernatant
was discarded. The tissue pellet was then digested with 40 mL of
PBS containing 0.15% pronase (Sigma) for 10 minutes at 37°C.
Cell culture medium (M-199, Gibco) containing 10% fetal bovine
serum (FBS; Gibco), 100 U/mL penicillin, and 100 mg/mL strep-
tomycin was added to the cell containing the supernatant to neu-
tralize enzymatic activity. After centrifugation, cells were pre-
plated on a noncoated culture dish for 30 minutes to try to purify
the cell pellet as much as possible. Then the supernatant, which
contained a higher cell population of satellite cells than before
preplating, was transferred into 60-mm laminin-coated culture
dishes (Becton Dickinson). The SKMCs were subcultured once
during the period of culturing (5-6 days) before cryopreservation.
Satellite cells had to be subcultured in approximately 60% conflu-
ence to prevent them from forming myotubes in culture. As a
result, the culture period was shorter in SKMCs than VSMCs.
VSMCs were isolated as previously described.7 In brief, 0.5
mL of PBS containing 0.2% Type II collagenase (Worthington),
0.4% trypsin (DIFCO), and 0.02% glucose was injected into the
aortic lumen and incubated for 20 minutes at 37°C. The lumen was
flushed with PBS to remove endothelial cells. The aorta was
minced and incubated in 12.5 mL of the same enzyme for 15
minutes at 37°C. The cells in the supernatant were transferred into
Iscove’s modified Dulbecco’s cell culture medium (IMDM;
Gibco) containing 10% FBS, 0.1 mmol/L -mercaptoethanol, 100
U/mL penicillin, and 100 mg/mL streptomycin. After centrifuga-
tion, the cell pellet was resuspended in the culture medium and
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plated into a 10-mm culture dish. The VSMCs were subcultured
once during the period of culturing (14 days) before cryopreser-
vation. Before each subculture and transplantation, VSMCs
reached approximately 80% confluence. The VSMCs expanded
less rapidly in culture compared with the SKMCs and were main-
tained longer in culture to achieve equal cell numbers in both groups.
Cryopreservation. When the cells in passage 2 reached certain
confluence (60% in SKMCs and 80% in VSMCs), the cells were
cryopreserved, as previously reported.10 Briefly, the cultured cells
were washed with PBS and then detached from the culture dish
and separated from each other by means of incubation with 0.05%
trypsin in PBS for 2 minutes. After the addition of culture medium
(M-199 for SKMCs and IMDM for VSMCs) containing 10% FBS,
the cell suspension was centrifuged. The cell pellet was then
resuspended in the cryopreservation solution (10% dimethylsulf-
oxide, 20% FBS, and 70% culture medium) and stored in
cryovials. The cryovials were then frozen and stored in liquid
nitrogen for a 3-week period. Before transplantation, cryopre-
served cells were thawed quickly in a water bath at 37°C and
plated on a laminin-coated dish with M-199 containing 10% FBS
for SKMCs (5  103 cells/cm2) or on an uncoated dish with
IMDM containing 10% FBS for VSMCs (2.6  103 cells/cm2).
The cells were cultured until the time of transplantation (3 days for
SKMCs and 7 days for VSMCs).
Cell identification. Approximately 2% of the cultured SKMCs
were kept in the cell culture incubator after thawing to identify
myotube formation. The cultured SKMCs and VSMCs were iden-
tified immunohistochemically by using monoclonal anti-MyoD1
antibody (Dako) and anti--smooth muscle actin antibody
(Sigma), respectively, as previously described.3
Figure 1. Experimental design. A, differential in vitro effects of cryopreservation on muscle cell growth and
morphology from myopathic versus normal donor hamsters. Open bars indicate cells from normal hamsters, and
shaded bars indicate cells from cardiomyopathic BIO53.58 hamsters. B, In vivo effects of muscle cell transplan-
tation from cardiomyopathic donors for use in dilated cardiomyopathy after prior cryopreservation.
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Assessment of Cell Growth
Cell growth rates were compared among cryopreserved and non-
cryopreserved cells from cardiomyopathic hamsters (BIO) and
normal hamsters to determine the effect of cell type on growth.
This comparison was done for both VSMCs and SKMCs (BIO
VSMCs, n  4; normal VSMCs, n  4; BIO SKMCs, n  4;
normal SKMCs, n  4). Because passages before and after cryo-
preservation correspond to passage 2 and passage 3, respectively,
growth rates before and after cryopreservation were compared
with those in passage 2 and passage 3 of noncryopreserved cells.
Cell growth rate was calculated at passage 2 (before cryopreser-
vation) and 3 (after cryopreservation), and it was expressed as
doubling time.
Identification of the Transplanted Donor Cells In Vivo
The cultured SKMCs (n  2) and VSMCs (n  2) were labeled
with the thymidine analog 5-bromo-2'-deoxyuridine (BrdU) before
transplantation to identify the transplanted cells in the recipient
myocardium. When the cells reached 50% confluence, 25 mL of
0.4% BrdU solution was added to culture dishes and incubated for
48 hours before transplantation. After cell counting, the proportion
of BrdU-incorporated cells was adjusted to 15% for each cell
injection.
Cell Preparation and Transplantation
Cell preparation. The cultured cells were washed 3 times with
PBS to remove dead cells and debris. The cells were then detached
from the cell culture dish and separated by adding 0.05% trypsin
in PBS to the culture dish for 2 minutes. After the addition of 10
mL of culture medium, the cell suspension was centrifuged at 580g
for 5 minutes. The cell pellet was then resuspended in culture
medium to reach a concentration of 100 106 cells/mL. A volume
of 0.04 mL of cell suspension or culture medium alone was then
transplanted into each heart.
Cell transplantation. The recipient hamsters were anesthe-
tized with ketamine (20 mg/kg body weight intramuscularly),
followed by an intraperitoneal injection of pentobarbital (30 mg/kg
body weight). The anesthetized hamsters were intubated, and
positive pressure ventilation was maintained with a Harvard ven-
tilator (Model 683, South Natick). The respiratory rate was set at
60 cycles/min, with a tidal volume of 1.5 mL of oxygen-supple-
mented room air. The heart was exposed through a 3-cm left lateral
thoracotomy. By using a tuberculin syringe, a single injection on
the surface of the anterior LV free wall delivered 4  106 cells in
a 0.04-mL total volume. The needle was inserted into the apex and
tracked up toward the base of the heart. The cells were slowly
released while the needle tip was withdrawn, leaving cells through-
out the anterolateral left ventricle from base to apex between the
left anterior coronary artery and the great cardiac vein on the
posterior wall. The transplant area covered approximately 40% of
the surface of the anterolateral left ventricle in all animals injected.
Control animals were injected with culture medium by using the
same technique as used for the cell-transplanted animals. The
muscle layer and skin incision were closed with 5-0 vicryl sutures.
The hamsters recovered from the operation in a warm environment
and were electrocardiographically monitored for 4 hours. Chlor-
amphenicol (Chloromycetin; Parke-Davis, 0.1 mg/kg administered
intramuscularly) and buprenorphine (0.01-0.05 mg/kg adminis-
tered subcutaneously) were given for 2 days after the operation.
Cyclosporine, at a dose of 5 mg/kg body weight per day, was
administered subcutaneously to all groups each postoperative day.
The hamsters were housed in cages with filter tops.
Determination of LV Function
Five weeks after cell transplantation, heart function was evaluated
in all groups by using a Langendorff preparation. The hamsters
were anesthetized, and heparin sodium (100 units) was adminis-
tered intravenously. The heart was quickly isolated and perfused in
a Langendorff apparatus with filtered Krebs-Henseleit buffer
(NaCl, 118 mmol/L; KCl, 4.7 mmol/L; KH2PO4, 1.2 mmol/L;
CaCl2, 2.5 mmol/L; MgSO4, 1.2 mmol/L; NaHCO3, 25 mmol/L;
and glucose, 11 mmol/L; pH 7.4) equilibrated with 5% carbon
dioxide and 95% oxygen. A latex balloon was passed into the left
ventricle through the mitral valve and connected to a pressure
transducer (model p10EZ, Viggo-Spectramed) and differentiator
amplifier (model 11-G4113-01, Gould Instrument System Inc).
After 30 minutes of stabilization, the balloon size was increased by
0.005-mL increments from 0.005 mL to 0.065 mL by means of the
stepwise addition of saline. Coronary flow was measured in trip-
licate by means of timed collection in the empty beating state.
After measuring coronary flow for 1 minute, heart rate and systolic
and diastolic LV pressures were recorded at each balloon volume.
Developed pressure was calculated as the difference between the
systolic and diastolic pressure. After completion of the measure-
ments, the hearts were arrested with coronary perfusion of 5 mL of
20% KCl solution. The passive diastolic pressure in the arrested
heart was recorded at each balloon volume in 0.005-mL incre-
ments from 0.005 mL to 0.09 mL by means of the stepwise
addition of saline. After evaluation of cardiac function, hearts were
weighed and fixed with 10% formaldehyde for histology.
Geometric Mapping of the Left Ventricle
The LV volume was measured, as previously described.7,8,11,12
Briefly, the hearts were fixed in LV distension (30 mm Hg) with
10% phosphate-buffered formalin for 48 hours and sectioned in the
short axis (1-mm thickness) to yield 6 segments. The segments
were photographed and quantified by using computerized planim-
etry (Jandal Scientific Sigma-Scan). Both the apical and the basal
sides of each segment were evaluated. The luminal area of the left
ventricle for each segment was determined by calculating the area
as outlined by the endocardial circumference. The mean luminal
area was determined by calculating the mean luminal area for both
the apical and basal sides of each segment. The total LV volume
was calculated as the sum of the luminal area for each segment
multiplied by the uniform thickness of 1 mm. The average of the
LV anteroposterior diameter and the septolateral diameter at the
midpapillary section was calculated. The average of 4 opposite LV
walls (anterior, posterior, septal, and lateral) was also calculated.
The ratio of LV wall thickness to LV diameter was calculated.
Histology
After planimetry, heart segments were embedded in paraffin, sec-
tioned at a 10-m thickness, and mounted on glass slides. Hema-
toxylin and eosin and elastica Masson trichrome staining were
performed, as described by the manufacturer’s specifications
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(Sigma). Immunohistochemical staining3 was performed for BrdU,
muscle-specific actin (Dako), skeletal fast myosin heavy chain
(Sigma), cardiac-specific -myosin heavy chain (Chemicon), and
-smooth muscle actin (Sigma).
Statistical Analysis
Results are presented as means  SD. SAS system software was
used for all analyses (SAS Institute). For the cell-growth study and
geometric analysis, comparisons of continuous variables among
more than 2 groups were performed by using 1-way factorial
analysis of variance. If the F ratio was significant, the Scheffe test
was used to specify differences between groups. Function data
were evaluated for the 4 groups by means of analysis of covariance
by using intraballoon volume as covariance and peak systolic
pressure, developed pressure, and end-diastolic pressure as depen-
dent variables. Main effects were group, balloon volume, and
interaction of group by balloon volume. If a significant difference
was identified, multiple pairwise comparisons were performed to
specify between-group differences.
Results
In Vitro Cell Growth
The rate of cell growth in vitro was evaluated by means of
serial cell counting and calculating the doubling time (Table
1). In normal hamsters smooth muscle cells grew faster than
SKMCs (P  .008 at passage 2). However, in cardiomyo-
pathic hamsters the capacity for smooth muscle cells to
proliferate was altered. In cardiomyopathic hamsters
VSMCs grew more slowly than SKMCs (P  .003 at
passage 2 and P  .02 at P3). We next evaluated the effects
of prior cryopreservation and cell storage on the subsequent
growth rate of the cells after thawing and reanimation in
culture. Cryopreservation had a profound effect on limiting
the growth rate of the VSMCs isolated from cardiomyo-
pathic donors. Interestingly, VSMCs isolated from normal
hamsters without the genetic cardiomyopathy were not af-
fected by prior cryopreservation. SKMCs taken from either
normal or cardiomyopathic donor hamsters were not signif-
icantly influenced by cryopreservation.
In Vitro Cell Morphology and Identification
To further assess the suitability of these muscle cells for
transplantation, we next examined their morphologic char-
acteristics and the expression of cell-specific markers by
means of immunohistochemistry. Before cryopreservation,
the cardiomyopathic VSMCs were larger than the SKMCs
(Figure 2). In addition, the morphology of the VSMCs from
cardiomyopathic donors contrasted with the smaller spin-
dle-shaped appearance of the smooth muscle cells from
normal donors, indicating that the health of these cells was
compromised even before cryopreservation. Also in keep-
ing with the cell proliferation data, no morphologic differ-
ences were noted between the SKMCs from normal and
cardiomyopathic donors, suggesting that these cells were
healthy in culture before cryopreservation. After cryo-
preservation and before transplantation, the purity of the
cells was assessed by means of immunohistochemistry in 4
culture dishes for each group. Most (61.5%  5%) of the
SKMCs stained positively for MyoD1, and 93%  4% of
the VSMCs stained positively for -smooth muscle actin
(Figure 3). Multinuclear myotubes were seen in all SKMC
plates after differentiation in serum-free media.
LV Function
LV function was assessed 5 weeks after cell transplantation
by means of isolated heart perfusion with a Langendorff
preparation. Heart rate and coronary flow were not signifi-
cantly different between normal media-injected control sub-
jects and cell-transplantation groups at different balloon
volumes (data not shown). Figure 4 demonstrates that LV
systolic function was preserved by muscle cell transplanta-
tion from cardiomyopathic donors. Both peak systolic pres-
sure and developed pressure were significantly greater after
transplantation of VSMCs and SKMCs than that seen in
media-injected control hearts. Diastolic function did not
differ significantly among the 4 groups. Transplantation of
cryopreserved SKMCs that appeared healthy in vitro re-
sulted in a marked preservation of heart function similar to
that seen in normal hamster hearts. In contrast, cryopre-
served VSMCs that were abnormal in vitro had only a
moderate beneficial effect on cardiac function after trans-
plantation.
Geometric Maps of the Left Ventricle
LV geometry was assessed on the basis of computerized
planimetry of heart sections. The SKMC- and VSMC-trans-
TABLE 1. Doubling time of donor cells
A. Doubling time (hours)
P2 P3
SKMC normal 56 12 50 4
SKMC BIO 35 17 50 1
VSMC normal 21 6 36 13
VSMC BIO 60 12* 159 50†
B. Effect of prior cryopreservation at passage 2 on doubling time (hours)
after thawing at passage 3
Noncryopreserved Cryopreserved
SKMC normal 50 4 76 5
SKMC BIO 50 1 60 17
VSMC normal 36 3 40 20
VSMC BIO 159 50 271 59‡
P, Passage.
*P  .001 versus normal VSMC at P2.
†P  .01 versus normal VSMC at P3.
‡P  .001 versus noncryopreserved BIO VSMC at P3.
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planted chamber volumes (65.9  5 and 76.3  14 L,
respectively) were smaller (SKMCs, P  .001; VSMCs, P
 .02) than those of media-injected control hamsters (96.7
 16 L), indicating that cell transplantation limited ven-
tricular dilatation and remodeling. Adverse chamber remod-
eling was attenuated most profoundly after transplantation
of cryopreserved SKMCs, and chamber volumes ap-
proached those of age-matched normal hearts (59.8  6
Figure 2. Photomicrographs of cultured VSMCs (A and B) and SKMCs (C and D) obtained from cryopreserved
normal and cardiomyopathic hamsters. The normal spindle-shaped VSMCs contrasted in appearance with the
cardiomyopathic VSMCS that were larger and not spindle shaped. The normal and cardiomyopathic SKMCs were
similar in appearance.
Figure 3. Photomicrographs of cultured cyropreserved BIO 53.58 SKMCs (A; original magnification 100) and
VSMCs (B; original magnification 100). The SKMCs stained positively for myoD, and the VSMCs stained positively
for -smooth muscle actin.
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L). In addition, measurement of LV wall thickness at the
level of the papillary muscles indicated that wall thinning
was prevented by cell transplantation (Table 2).
Histology
As expected, all hearts from BIO 53.58 hamsters showed
extensive myolysis, with dense replacement fibrosis char-
Figure 4. Peak systolic, developed, and end-diastolic pressures of normal, SKMC, VSMC, and control hearts with
increasing balloon volumes. The peak systolic and developed pressures of the SKMC and normal hearts were
significantly higher than the pressures of the VSMC hearts, which were greater than those of the control hearts.
Diastolic function was not significantly different.
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acteristic of the underlying cardiomyopathic process. These
changes were absent in normal hearts. Transplantation of
both SKMCs and VSMCs resulted in the formation of
muscle tissue in the anterior aspect of the left ventricle
(Figure 5). The engrafted cells were evident by means of
hematoxylin and eosin staining (Figure 6, A and B) and
confirmed as the transplanted cells by means of BrdU stain-
ing (Figure 6, C and D). The SKMCs were found in both the
subepicardial and midmyocardial regions, whereas VSMCs
localized to the subepicardial layer. Although transplanted
cells were observed in the heart after a period of 5 weeks,
the VSMC transplantation formed a thin and sparsely pop-
ulated tissue, as assessed by means of BrdU staining. This
suggests limited engraftment with VSMCs compared with
SKMCs. Elastin Masson trichrome staining (Figure 6, E and
F) demonstrated an extensive extracellular elastin matrix
surrounding the SKMCs compared with the VSMCs. In
contrast, dense fibrillar collagen rather than an organized
extracellular matrix surrounded the VSMCs. In addition, the
engraftment of these allogeneic cells was associated with a
mild lymphocytic infiltration (Figure 6, A and B), suggest-
ing that a chronic process of mild rejection occurred despite
daily cyclosporine treatment. The engrafted SKMCs stained
positively for muscle-specific actin (Figure 7, A) and skel-
etal muscle fast myosin heavy chain (Figure 7, B) but did
not stain for cardiac -myosin heavy chain (Figure 7, C).
The engrafted VSMCs stained positively for -smooth mus-
cle actin (Figure 7, D).
Discussion
This study offers the following observations: (1) extracar-
diac muscle cells can be isolated, cultured, cryopreserved,
and stored for at least 3 weeks and injected into a cardio-
myopathic heart, and the cells will engraft, limit cardiac
thinning and dilatation, and preserve global systolic func-
tion for at least 5 weeks; (2) donor cells that exhibit mor-
phologic abnormalities and decreased growth in vitro result
in diminished engraftment and less successful preservation
of ventricular size and function; and (3) with inherited
cardiomyopathies, some peripheral muscle cells might also
be affected by the myopathic process limiting their benefi-
cial effects after cell transplantation. These insights might
be helpful in designing clinical trials intended to limit
cardiac thinning and dilatation in patients with an inherited
dilated cardiomyopathy.
Cell Types
We previously demonstrated that the transplantation of al-
logeneic heart cells and autologous smooth muscle cells
prevented cardiac thinning and dilatation and preserved
systolic ventricular function similar to that seen in other cell
types.7,8 We used heart cells from young (4-week-old) BIO
53.58 hamsters before cardiomyopathy developed. Our pre-
Figure 5. Location of bromodeoxyuridine-labeled SKMCs trans-
planted in the anterior left ventricle of the cardiomyopathic BIO
53.58 hamster. The labeled cells (arrows) were identified only in
the LV anterior wall.
TABLE 2. LV wall thickness (mm)
Normal
(n  7)
Control
(n  11)
VSMC
(n  10)
SKMC
(n  10)
Anterior wall 2.2 0.2 1.6 0.2* 2.1 0.4 2.3 0.3
Posterior wall 1.7 0.3 1.4 0.1† 1.8 0.4 1.7 0.2
Septum 1.4 0.2 1.3 0.2 1.5 0.3 1.6 0.2‡
Lateral wall 1.9 0.2 2.0 0.3 2.3 0.4§ 2.3 0.3
Mean thickness 1.8 0.2 1.6 0.1¶ 1.9 0.2 2.0 0.2
Wall thickness (mean  SD) was measured at the level the papillary muscles for the left ventricle.
The anterior, posterior, and lateral walls of the left ventricle in SKMC- and VSMC-transplanted hearts were thicker than the control walls.
*P  .001 versus normal, P  .001 versus VSMC, P  .001 versus SKMC.
†P  .005 versus normal, P  .001 versus VSMC, P  .002 versus SKMC.
‡P  .002 versus control.
§P  .04 versus normal.
P  .03 versus normal, P  .045 versus control.
¶P  .001 versus VSMC, P  .001 versus SKMC.
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vious study established a proof of concept, but heart cell
transplantation might not be clinically relevant if the heart
cells are abnormal and grow slowly ex vivo. Patients with a
progressive dilated cardiomyopathy could have abnormal
heart cells, which might not be suitable for transplantation.
Autologous smooth muscle cells might be ideal donor cells
to prevent congestive heart failure. Smooth muscle cells
respond to hemodynamic stresses by means of hyperplasia
and hypertrophy, and they rapidly establish an extracellular
matrix that communicates with the surrounding viable car-
diomyocytes. Therefore smooth muscle cells might be ideal
donor cells for cardiac regeneration. We previously demon-
strated that stomach smooth muscle cells engrafted in a
cryoinjured cardiac scar and preserved ventricular func-
tion.3 These cells responded to the hemodynamic stresses 4
weeks after transplantation by means of hyperplasia, but not
hypertrophy, to maintain wall thickness.3 Autologous
smooth muscle cells from the ductus deferens of adult
Figure 6. Hematoxylin and eosin–stained (HE), anti-bromodeoxyuridine–stained (BrdU), and elastica Masson
trichrome–stained (EMT) SKMC and VSMC transplants in the host BIO 53.58 hamster LV anterior wall. The SKMC
transplant contained many BrdU-labeled cells (C), was substantial, and had less fibrosis and more elastin (A and
E) than the VSMC transplant (B, D, and F). Some of the SKMCs had mature sarcomeres (inset, C). The VSMC
transplant tended to be localized to the subepicardium, whereas the SKMC transplant could be found in the
subepimyocardium and midmyocardium.
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(13-week-old) BIO 53.58 hamsters were expanded rapidly
ex vivo and engrafted in the anterior wall of cardiomyo-
pathic hamsters after transplantation.8 Cell engraftment pre-
vented cardiac dilatation and preserved ventricular function.
However, harvesting cells from the vas deferens might be
inconvenient in male patients and not possible in female
patients. Therefore in the present study we evaluated
VSMCs, which could be harvested from a peripheral vein in
patients at an early stage of cardiomyopathy. We used
allogeneic aortic smooth muscle cells from the cardiomyo-
pathic hamsters to mimic an autologous transplant. The
small size of the animals precluded an actual autologous
transplantation of VSMCs. Interestingly, we found that the
VSMCs from cardiomyopathic donors had an abnormal
morphology and a restricted growth pattern. This was not
the case for SKMCs or VSMCs from normal donors.
The BIO 53.58 hamster has a muscular dystrophy from
an inherited -sarcoglycan gene deficiency,13,14 which in-
volves cardiac, skeletal, and smooth muscle to varying
degrees. The phenotype is most pronounced in mature
VSMCs as a result of disruption of the sarcoglycan-sarco-
span complex found only in vascular smooth muscle.10 In
fact, microvascular spasm resulting in diffuse microinfarcts
is believed to mediate the cardiomyopathy associated with
this genetic defect.15,16 In our study the abnormal VSMCs
grew slowly ex vivo, and this characteristic predicted the
limited engraftment of these cells in the anterior wall of the
cardiomyopathic hamsters. These slow-growing cells pro-
duced fewer engrafted cells and induced only a modest
improvement in systolic function. These results suggest that
ex vivo morphology and growth rates can be used to predict
the success of subsequent cell transplantation. In some
patients with a cardiomyopathy, VSMCs might be normal,
and results comparable with those of the SKMC are antic-
ipated. In support, normal VSMCs have been successfully
used for the creation of autologous vascular grafts.17
Cryopreservation
Both SKMCs and VSMCs successfully limited cardiac di-
latation and preserved ventricular function after cryopreser-
vation for 3 weeks. However, the tolerance of the cells to
cryopreservation was different. Donor cells showing abnor-
malities in vitro were further compromised after a period of
cryostorage. These results suggest that the clinical applica-
tion of cryopreservation for storage of donor cells should be
used with caution if the cells show abnormal morphology or
poor growth in the initial culture period. In a previous study
fetal cardiomyocytes proliferated and beat in vitro and en-
Figure 7. Immunohistochemical staining of the SKMC and VSMC transplants. The SKMC transplant stained
positively for muscle-specific actin (MSA; A) and skeletal muscle fast myosin heavy chain (SMHC; B) and
negatively for -myosin heavy chain (MHC; C). The VSMC transplant stained positively for -smooth muscle actin
(SMA; D). Arrows indicate positive staining.
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grafted into the cryoinjured heart after 4 weeks of cryo-
preservation.18 However, in both studies cryopreservation
decreased the rate of proliferation and probably reduced cell
survival after cardiac implantation. Cryopreservation might
permit elective cell transplantation early in the course of
cardiac decompensation in patients with a cardiomyopathy.
However, more cells might need to be implanted after
cryopreservation to obtain the same degree of enhancement
of ventricular function.
Improvement in Ventricular Function
The mechanism by which SKMCs and VSMCs preserved
ventricular function remains obscure. Previous studies have
not conclusively identified synchronous contraction of the
SKMCs implanted in injured myocardial regions. Therefore
active cellular contraction is unlikely to explain the pre-
served systolic function seen after cell engraftment. In our
study the implanted cells established a rich extracellular
matrix, with connections to the remaining viable cardiomy-
ocytes. Improvements in function could have resulted from
the cells actively establishing an organized interstitial ma-
trix, which limited dilatation and thinning. Importantly, the
apparent health of the cells in vitro predicted the degree of
engraftment and the subsequent benefits on cardiac structure
and function after transplantation. These data indicate that
the health of the donor cells influences the process of
cellular engraftment and suggest that the benefits of cell
transplantation are dependent on the number of cells that
successfully engraft in the host myocardium. Although wall
thickness increased equally by using the different cell types
transplanted, the SKMCs were healthy in culture and af-
forded greater benefits on limiting dilatation and preserving
cardiac function than the abnormal VSMCs. These data
might imply that transplanted cells limit remodeling in the
failing heart as a result of active cellular events after en-
graftment and not as a result of passive ventricular con-
straint from increased wall thickness.
Clinical Implications
Cryopreserving donor cells might allow for targeted cell
therapy at predetermined intervals in the progression of
global cardiac failure. For example, for patients with com-
pensated dilated cardiomyopathy, targeted therapy at the
onset of significant chamber dilatation and increased wall
stress might prevent decompensation that would otherwise
lead to whole organ transplantation, ventricular device as-
sistance, or death. With the aid of cryopreservation, harvest
of muscle cells when the patient is both physiologically and
pharmacologically stable will be possible. This available
pool of autologous donor cells will be available for a second
transplantation if decompensation should occur. After a
period of hemodynamic unloading while on mechanical
assistance, cell transplantation might provide a stabilizing
addition to the transient benefits offered by the process of
reverse remodeling. Although the specific molecular effects
of cryopreservation on donor cells were not examined, in
this study the important clinical benefits on myocardial
remodeling and cardiac function were not lost as a result of
donor cell cryostorage. Our initial observations have now
been extended in a more clinically useful framework that
favors the future use of cryopreservation for targeted cell
therapy.
Limitations and Summary
Some of our study’s limitations deserve mention. We were
forced to explore allotransplantation of noncardiac muscle
cells because the small size of the hamsters made autotrans-
plantation of vascular smooth muscle difficult. Despite the
use of cyclosporine, rejection was not completely elimi-
nated, and this might have influenced the assessment of
engraftment. However, the ability of the allogeneic noncar-
diac muscle cells to engraft and remain viable in diseased
myocardium under hemodynamic strain after prior cryo-
storage makes the prospect of similar autogenous cells even
more promising. Assessment of LV function by the use of
the Langendorff perfusion apparatus has been criticized in
the past, but echocardiography and in vivo catheter assess-
ment in such a small-animal model has not proved reliable
in our hands. The lack of specific data on the differential
effects of cryopreservation on the cell types used in the
study make interpretation of the results more difficult, a
problem that could be addressed in future studies. Addition-
ally, given that the mechanism by which transplanted cells
influence cardiac remodeling and function is unknown, in-
terpretation of the data is limited. Future studies to uncover
the specific molecular and cellular effects of cell transplan-
tation in globally dysfunctional myocardium are necessary
before this novel therapy can become a substantive clinical
approach for heart failure.
In summary, noncardiac muscle cells from cardiomyo-
pathic donors can be successfully expanded in culture, cryo-
preserved, and later transplanted with significant engraft-
ment at 5 weeks, despite an ongoing cardiomyopathic
process. Cryopreserved SKMCs and VSMCs maintained
chamber geometry and cardiac function in failing hearts
after transplantation. These data suggest a clinically appli-
cable and effective approach for ventricular restoration with
cell-transplantation therapy for patients with inherited di-
lated cardiomyopathy.
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